Pearls

Cannabis-derived compounds: What you need to know

Author and Disclosure Information

 

References

Questionable claims about CBD

Some manufacturers market CBD products as having a variety of health benefits for both humans and pets, but most of these claims are unsubstantiated.1 The FDA has issued warning letters to several manufacturers who have marketed CBD products as producing therapeutic effects.5

Under the Federal Food, Drug, and Cosmetic Act, any products intended to have a therapeutic effect are considered drugs, and unapproved drugs cannot be distributed or sold in interstate commerce.1 Cannabidiol products cannot be sold as dietary supplements.1 In addition, food products containing CBD cannot be introduced or delivered for introduction into interstate commerce.1 Many CBD products do not contain the amount of CBD advertised, and some contain contaminants such as pesticides and heavy metals.1 Also, CBD products can affect the therapeutic effectiveness of prescription medications.

Discuss CBD with your patients

Ask your patients if they use CBD and, if so, find out which product(s), the quantity and frequency of use, and any effects they have experienced from using them. Patients can report any adverse effects from CBD products to the FDA’s MedWatch program (www.accessdata.fda.gov/scripts/medwatch/). Tell your patients that there is limited or inconclusive evidence regarding the therapeutic efficacy of over-the-counter CBD products for any medical or psychiatric condition. Encourage your patients to be open with you about using these products, so you can make appropriate treatment decisions.

Pages

Recommended Reading

COVID-19: Optimizing therapeutic strategies for children, adolescents with ADHD
MDedge Psychiatry
FDA clears first brain stimulation device to help smokers quit
MDedge Psychiatry
Adolescent e-cigarette use: A public health crisis
MDedge Psychiatry
Fecal transplant shows promise in reducing alcohol craving
MDedge Psychiatry
High schoolers prefer tobacco as vapor, not smoke
MDedge Psychiatry
Reworked OxyContin fails to cut overall opioid abuse, FDA panel says
MDedge Psychiatry
New acute pain guidelines from the ACP and AAFP have limitations
MDedge Psychiatry
Is psychiatry coddling the American mind?
MDedge Psychiatry
What to do when a patient is not ready to stop smoking
MDedge Psychiatry
COVID-19 shutdown fuels sharp rise in alcohol use
MDedge Psychiatry